Lingli Huang

Lingli Huang

Auto-generated profile, based on publicly available information

Lingli Huang

National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA (Ministry of Agriculture) Key Laboratory for Detection of Veterinary Drug Residues, Wuhan, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2015 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
XWXu Wang
Xu Wang
ZTZiqiang Tan
Ziqiang Tan
GCGuyue Cheng
Guyue Cheng
Awais IhsanAwais Ihsan
Awais Ihsan
LHLingli Huang
Lingli Huang
ZYZonghui Yuan
Zonghui Yuan

5 November 2015 in Food Additives & Contaminants: Part A
Verified
Journal Article
Closed access
LHLingli Huang
Lingli Huang
Zhoumeng LinZhoumeng Lin
Zhoumeng Lin
XZXuan Zhou
Xuan Zhou
MZMeiling Zhu
Meiling Zhu
RGRonette Gehring
Ronette Gehring
ZYZonghui Yuan
Zonghui Yuan
Physiologically based pharmacokinetic (PBPK) models are powerful tools to predict tissue distribution and depletion of veterinary drugs in food animals. However, most models only simulate the pharmacokinetics of the parent drug without considering their metabolites. In this study, a PBPK model was developed to simultaneously describe the depletion in pigs of the food animal antimicrobial agent cyadox (CYA), and its marker residue 1,4-bisdesoxycyadox (BDCYA). The CYA and BDCYA sub-models included blood, liver, kidney, gastrointestinal tract, muscle, fat and other organ compartments. Extent of plasma-protein binding, renal clearance and tissue-plasma partition coefficients of BDCYA were measured experimentally. The model was calibrated with the reported pharmacokinetic and residue depletion data from pigs dosed by oral gavage with CYA for five consecutive days, and then extrapolated to exposure in feed for two months. The model was validated with 14 consecutive day feed administration data. This PBPK model accurately simulated CYA and BDCYA in four edible tissues at 24–120 h after both oral exposure and 2-month feed administration. There was only slight overestimation of CYA in muscle and BDCYA in kidney at earlier time points (6–12 h) when dosed in feed. Monte Carlo analysis revealed excellent agreement between the estimated concentration distributions and observed data. The present model could be used for tissue residue monitoring of CYA and BDCYA in food animals, and provides a foundation for developing PBPK models to predict residue depletion of both parent drugs and their metabolites in food animals. Graphical Abstract

26 August 2021 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
FWFang Wang
Fang Wang
WLWanhe Luo
Wanhe Luo
YPYuanhu Pan
Yuanhu Pan
WQWei Qu
Wei Qu
SXShuyu Xie
Shuyu Xie
玉王玉莲 王
玉莲 王

1 January 2021 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
WLWanhe Luo
Wanhe Luo
DWDehai Wang
Dehai Wang
HQHua Qin
Hua Qin
DCDongmei Chen
Dongmei Chen
YPYuanhu Pan
Yuanhu Pan
SXShuyu Xie
Shuyu Xie
Luo W, et al. J Vet Sci. 2021 May;22(6):e41. https://doi.org/10.4142/jvs.2021.22.e41

26 February 2021 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
SXShuyu Xie
Shuyu Xie
XZXiaoqiu Zhang
Xiaoqiu Zhang
WLWanhe Luo
Wanhe Luo
KMKuiyu Meng
Kuiyu Meng
DCDongmei Chen
Dongmei Chen
ZYZonghui Yuan
Zonghui Yuan
Objectives: A ceftiofur hydrochloride long-acting oily suspension with no irritation was prepared by testing and optimizing the types and amounts of organic solvents, suspending agents, and surfactants. Methods: Its properties, stability, injection site irritation, in vitrorelease, and pharmacokinetics in pigs were evaluated. The optimum formulation was used ethyl oleate, aluminum monosterate, and span-80 as organic solvents, suspending agents, and surfactant, respectively. The drug microparticles were uniform long strip with size of 1.53 ± 0.11 μm and no agglomerations, and were evenly dispersed. The re-dispersed time, sedimentation rate and pH value of the suspension were 4 s under a magnetic shaker rotating at 20 r/min, 1 and 5.0, respectively. It could go through 7-gage needle smoothly with withdrawal volume of 9.9 mL/min. Results: The suspension showed good stability when stored away from light, no irritation at the injection site and sustained release in PBS buffer. After intramuscular administration, the drug concentration above 0.15 μg/mL was last for 120 h. Its elimination half-life (T1/2ke), mean residence time (MRT), and bioavailability were increased by 1.73, 1.62, and 2.16 times compared to Excenel®. Conclusion: The results suggested that the suspension had excellent sustained-release and will make ceftiofur hydrochloride more effective and convenient to use.

24 February 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
AHAnxiong Huang
Anxiong Huang
XLXun Luo
Xun Luo
ZXZihui Xu
Zihui Xu
LHLingli Huang
Lingli Huang
XWXu Wang
Xu Wang
Haihong HaoHaihong Hao
Haihong Hao
Clostridium perfringens causes significant morbidity and mortality in swine worldwide. Avilamycin showed no cross resistance and good activity for treatment of C. perfringens. The aim of this study was to formulate optimal regimens of avilamycin treatment for C. perfringens infection based on the clinical breakpoint (CBP). The wild-type cutoff value (COWT) was defined as 0.25 μg/ml, which was developed based on the minimum inhibitory concentration (MIC) distributions of 120 C. perfringens isolates and calculated using ECOFFinder. Pharmacokinetics–pharmacodynamics (PK-PD) of avilamycin in ileal content were analyzed based on the high-performance liquid chromatography method and WinNonlin software to set up the target of PK/PD index (AUC0–24h/MIC)ex based on sigmoid Emax modeling. The PK parameters of AUC0–24h, Cmax, and Tmax in the intestinal tract were 428.62 ± 14.23 h μg/mL, 146.30 ± 13.41 μg/ml,, and 4 h, respectively. The target of (AUC0–24h/MIC)ex for bactericidal activity in intestinal content was 36.15 h. The PK-PD cutoff value (COPD) was defined as 8 μg/ml and calculated by Monte Carlo simulation. The dose regimen designed from the PK-PD study was 5.2 mg/kg mixed feeding and administrated for the treatment of C. perfringens infection. Five respective strains with different MICs were selected as the infection pathogens, and the clinical cutoff value was defined as 0.125 μg/ml based on the relationship between MIC and the possibility of cure (POC) following nonlinear regression analysis, CART, and “Window” approach. The CBP was set to be 0.25 μg/ml and selected by the integrated decision tree recommended by the Clinical Laboratory of Standard Institute. The formulation of the optimal regimens and CBP is good for clinical treatment and to control drug resistance.